High Hampton Holdings Corp. Raises $19M in Private Placement | CashCropToday
0 Shares 338 Views

High Hampton Holdings Corp. Raises $19M in Private Placement

March 15, 2018
338 Views

High Hampton Holdings Corp. (CSE: HC) announced yesterday that the company successfully closed a non-brokered private placement of 31,703,565 units of the Company at a price of $0.60 per unit, to generate $19 million.

Each Unit contains one common share of High Hampton Holdings Corp. and one  warrant. Each warrant entitles investors to purchase one additional common share at an exercise price of $0.90 for 24 months following the closing of the offering.

High Hampton Holdings plans to use the proceeds gained in the offering to expand its development in Coachella Valley, to fund company operations, and enter into strategic partnerships.

High Hampton Holding’s wholly owned subsidiary CoachellaGro Corp., is focused on developments in the California cannabis market. Under the company’s umbrella is a 10.8 acre property situated near the proposed cannabis industrial park in Coachella. CoachellaGro has submitted its application for a conditional use permit for development of a full-service production facility in order to serve third party state licensed medical marijuana operators. The facility intended to contain security, infrastructure, equipment, labor, and supplies for growers.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
262 views
Market Watch
262 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
187 views
Global
187 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
184 views
Manufacturing
184 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: